Statement from the Competition Council regarding the economic concentration project involving the exclusive takeover of the company ‘Centre de Néphrologie et d’Hémodialyse Atlas SARL’ by the company ‘Diaverum Holding France SAS’, through the acquisition of 100% of its share capital and associated voting rights

In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the ‘operation summary’ below, containing information provided by the parties.

This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.

The publication of this statement does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented.

Names of the companies and individuals involved:

• The acquirer: ‘Diaverum Holding France SAS’;
• The target: ‘Centre de Néphrologie et d’Hémodialyse Atlas SARL’

Nature of the operation:

• Exclusive control takeover.

Economic sector concerned:

• Market for dialysis care services provided by the private sector.

Deadline for interested third parties to submit their observations:

• 10 days from the date of publication of this statement, i.e., January 29, 2024.

NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES

The Competition Council has received a notification of an economic concentration operation concerning the exclusive takeover of the company ‘Centre de Néphrologie et d’Hémodialyse Atlas’ (CNHA) by the company ‘Diaverum Holding France’ (Diaverum), through the acquisition of one hundred percent (100%) of its share capital and voting rights attached thereto.

Diaverum is a French simplified joint-stock company, with its registered office at 6, rue Béranger, 69006 Lyon, France, and registered with the Lyon Trade and Companies Register under number 498 723 873. Diaverum’s main activity is to invest in companies from various sectors (commercial, industrial, financial, or other), whether located in France or abroad.

CNHA is a Moroccan limited liability company, with a share capital of 22,200,000 dirhams, headquartered at 15, rue Alaouine, Boumharez, Guéliz, Marrakech, Morocco, registered with the Marrakech Trade Register under number 69813. CNHA’s purpose is to operate a nephrology and hemodialysis center named ‘Centre de Néphrologie et d’Hémodialyse Atlas’.

Done in Rabat, January 18, 2024